Skip to main content

Citrocarbonate Disease Interactions

There are 4 disease interactions with Citrocarbonate (sodium bicarbonate / sodium citrate).

Major

Alkalinizing agents (applies to Citrocarbonate) sodium/water balance

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Fluid Retention, Hypernatremia, Fluid Retention, Congestive Heart Failure, Hypokalemia, Hypernatremia

Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure. Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.

References

  1. "Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals PROD (2001):
  2. "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical PROD (2001):
Major

Laxatives (applies to Citrocarbonate) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
  4. "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc PROD (2001):
  5. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  6. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 6 references
Major

Laxatives (applies to Citrocarbonate) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet PROD (2001):
  5. "Product Information. Citrucel (methylcellulose)." SmithKline Beecham PROD (2001):
  6. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc PROD (2001):
  7. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  8. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 8 references
Moderate

Alkalinizing agents (applies to Citrocarbonate) acid/base balance

Moderate Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction, Alkalosis, Renal Dysfunction, Seizures, Alkalosis, Arrhythmias

Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions. Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis. Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release. Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function. Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.

References

  1. "Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company PROD
  2. "Product Information. Tham (tromethamine)." Abbott Pharmaceutical PROD (2001):
  3. "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical PROD (2001):

Citrocarbonate drug interactions

There are 164 drug interactions with Citrocarbonate (sodium bicarbonate / sodium citrate).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer